Hidradenitis Suppuritiva
Conditions
Interventions
Multiplex laser (PDL 6-8 J/m2, 10 ms, 7 mm and the 1064 nm Nd-YAG 30-40 J/m2, 40-50 ms, 7 mm) combined with methyl aminolevulinate (1 mm cream on and 5-10 mm around the lesion) versus multiplexlaser (
Sponsors
Erasmus MC, department of Dermatology and department of Immunology
Burg. s’ Jacobplein 51,
3015 CA Rotterdam,
The Netherlands
Eligibility
Inclusion criteria
Inclusion criteria: 1. Male/female 18 years or older of age; 2. Active moderate to moderate hidradenitis suppurativa (Hurley stage 1 or 2).
Exclusion criteria
Exclusion criteria: 1. Patients with a photoallergie or hypersensitivity to the active substance methyl aminolevulinate; 2. Pregnant women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To determine the efficacy of Multiplex laser whether or not combined with Metvix in patients with mild to moderate HS. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. To determine the percentage improvement of the lesions, the degree of pain and the degree of treatment satisfaction; 2. To determine the short-term side effects and tolerance of Multiplex laser whether or not combined with Metvix for the treatment of HS; 3. To determine the duration of remission during follow-up; 4. To dertermine changes of specific celpopulations. | — |
Contacts
Public ContactH.H. Zee, van der
Erasmus MC, department of Dermatology Dr. Molewaterplein 50
Outcome results
None listed